Abbott Plummets 2.17% Amid Regulatory Scrutiny as Volume Surges 40.74% to 940M Ranking 93rd

Abbott Laboratories (ABT) closed at $130.905 on August 11, 2025, down 2.17% amid heightened regulatory scrutiny in the medical device sector. The stock saw a 40.74% surge in trading volume, with $0.94 billion in turnover, ranking 93rd in the market.

Industry-wide pressures contributed to the decline. Recent safety concerns over Tandem Diabetes Care’s insulin pumps and Philips’ BiPAP machines have intensified regulatory oversight, amplifying investor caution. Abbott’s technical indicators show overbought conditions, with key support levels at $125.55 and $126.12. A breakdown below $131.48 could trigger further selling, while a rebound above $135 might attract short-term buyers.

Backtesting of a high-volume trading strategy revealed significant outperformance: purchasing the top 500 stocks by daily trading volume and holding for one day generated a 166.71% return from 2022 to present. This outpaced the benchmark by 137.53%, underscoring liquidity-driven momentum in volatile markets.